Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3454 in advanced biliary tract cancer with IDH1 mutation
NCT05987358Phase 3Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB3454 in biliary tract cancer (BTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2023; status: active, not recruiting.
02
Drugs
TQB3454
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05987358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987358.